Skip to content
A Green Sign – Lifestyle
Author:
Krystal Biotech, Inc.
Krystal Biotech to Report Third Quarter 2026 Financial Results on November 2, 2026
October 22, 2026
Krystal Biotech Announces Positive Clinical Data for New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression in Patients with Gorlin Syndrome
October 15, 2026
Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference
September 3, 2026
Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results
August 3, 2026
Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026
July 23, 2026
Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
May 18, 2026
Krystal Biotech to Present at BofA Securities 2026 Health Care Conference
May 7, 2026
Krystal Biotech Announces First Quarter 2026 Financial and Operating Results
May 4, 2026
Krystal Biotech to Present at Upcoming Scientific Conferences
April 30, 2026